Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
Returns on capital
Generate Biomedicines, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
33.0%
avg 36.5%
ROIC
-89.4%
avg -66.7%
ROA
-61.5%
avg -47.5%
Analysis
ROE is currently the strongest return metric at 33.0% versus its period average of 36.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Michael T. Nally | CEO & Director | USD 1.08M | 50 | — | — |
Jason E. Silvers | President & CFO | USD 772.9K | 54 | — | — |
Gevorg Grigoryan | Co-Founder & CTO | USD 738.02K | 45 | — | — |
Noubar Afeyan | Co-founder & Independent Chair of the Board | — | 63 | — | — |
Sahm Nasseri | Senior Vice President of Business Development & Strategy | — | 41 | — | — |
Beth Grous | Chief People Officer | — | 58 | — | — |
Molly Gibson | Co-Founder | — | — | — | — |
Aarif Khakoo | Chief Scientific Officer | — | 55 | — | — |
Daria Hazuda | Senior Vice President of Discovery Strategy | — | — | — | — |
Sean W. Martin | Secretary, Chief Legal Officer & General Counsel | — | 63 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$200,735.39
Net Transaction Value
−$200,735.39
Net selling
Most Active
ARNOLD FRANCES
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 29, 26Oct 29, 2026 | ARNOLD FRANCES Direct | Sell | $184.7K$184,733.39 |
| Sep 1, 26Sep 1, 2026 | ARNOLD FRANCES Direct | Sell | $16K$16,002.00 |
Summary
Insiders reported 0 buys worth $0.00 and 2 sells worth $200,735.39 over the last 12 months. That adds up to net selling of $200,735.39. ARNOLD FRANCES was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +38.6% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +38.6% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Generate Biomedicines, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about GENB's management, answered from reported figures.
Who manages GENB?
Generate Biomedicines, Inc. (GENB) lists 10 active executives. The top listed executive is Gevorg Grigoryan, Co-Founder & CTO.
Are GENB insiders buying or selling?
Recent insider activity shows net selling of $200,735.39.
Continue the stock analysis
Jump to another research area for this company.